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Abstract
Introduction: The interdependence between endotoxemia, gram negative (GN) bacteremia and mortality has
been extensively studied. Underlying patient risk and GN bacteremia types are possible confounders of the
relationship.
Methods: Published studies with ≥10 patients in either ICU or non-ICU settings, endotoxemia detection by limulus
assay, reporting mortality proportions and ≥1 GN bacteremia were included. Summary odds ratios (OR) for
mortality were derived across all studies by meta-analysis for the following contrasts: sub-groups with either
endotoxemia (group three), GN bacteremia (group two) or both (group one) each versus the group with neither
detected (group four; reference group). The mortality proportion for group four is the proxy measure of study level
risk within L’Abbé plots.
Results: Thirty-five studies were found. Among nine studies in an ICU setting, the OR for mortality was borderline
(OR <2) or non-significantly increased for groups two (GN bacteremia alone) and three (endotoxemia alone) and
patient group one (GN bacteremia and endotoxemia co-detected) each versus patient group four (neither
endotoxemia nor GN bacteremia detected). The ORs were markedly higher for group one versus group four (OR
6.9; 95% confidence interval (CI), 4.4 -to 11.0 when derived from non-ICU studies. The distributions of Pseudomonas
aeruginosa and Escherichia coli bacteremias among groups one versus two are significantly unequal.
Conclusions: The co-detection of GN bacteremia and endotoxemia is predictive of increased mortality risk versus
the detection of neither but only in studies undertaken in a non-ICU setting. Variation in GN bacteremia species
types and underlying risk are likely unrecognized confounders in the individual studies.
Introduction
The prognostic value of endotoxemia detection has been
studied in more than forty studies [1-41]. Conflicting
conclusions became apparent from the earliest studies
undertaken [24,25,41].
The prognostic value remains unresolved despite 17
large studies including more than 2,000 patients
[11,21,24-27,29-33,35-41]. On the one hand, in six studies
endotoxemia was predictive of septicaemia onset or severe
illness [11,21,24,38,40] and hospital mortality [11,24,26]
among studies of hospitalized patients unrestricted to an
ICU setting. On the other hand, 13 studies including eight
among patients restricted to ICU settings found the detec-
tion of endotoxemia either did not predict organ dysfunc-
tion or mortality [25,27,30,31,33,39,41], predicted
mortality but not organ dysfunction [35], predicted organ
dysfunction but not mortality [29,32,37,38], or predicted
mortality only when the level of endotoxemia was com-
bined within a lipo-polysaccharide cytokine score [36]. In
only three [11,21,24] of these 17 studies did the mortality
difference between the groups positive versus negative for
endotoxemia exceed 20 percentage points.
Several additional clinical observations indicate that the
inter-relation between endotoxemia, gram negative (GN)
bacteremia and outcome is not simple [42-44]. Less than
two thirds of patients with GN bacteremia have endotox-
emia detected and vice versa [42]. The concordance with
GN bacteremia varies with GN bacteremia species type
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[43]. The structure function activity of lipid-A, the biolo-
gically active component of endotoxin differs for different
GN bacteria [45]. Furthermore, the impact of underlying
risk of death is a key factor in the clinical setting [46,47]
but is difficult to investigate in laboratory studies [48-52].
These factors illustrate the ‘disconnect’ between attempts
to study sepsis in animal models versus the clinical set-
ting [50]. The objective here is to evaluate the GN bacter-
emia species type and underlying patient risk as possible
confounding factors of the prognostic value of endotoxe-
mia as detected using the limulus assay in published clin-
ical studies of patients across a broad spectrum of risk.
Materials and methods
Data sources
A computerized search of PUBMED (including Medline)
was undertaken using the following key words in the title
or abstract; ‘endotoxemia’, ‘limulus’ and was restricted to
studies in humans. This search was supplemented by a
hand-search for studies reporting mortality outcome data
in relation to endotoxemia detection and detection of
GN bacteremia with blood culture for patient groups at
risk of GN bacteremia. This search has been performed
repeatedly over two decades [44] up to April 2012 as
detailed previously [43,44]. A call for data was published
[53] and authors were contacted for additional data to
enable inclusion. The flow chart of the literature search
strategy and study accrual and disposition is detailed in
Figure 1.
Study selection
The inclusion and exclusion criteria and numbers of
studies excluded are detailed in Figure 1. The following
inclusion criteria were used; (1) limulus assay used for
endotoxemia detection, (2) at least one patient with GN
bacteremia, (3) at least ten patients in the study, (4) at
least five patients in group four, (5) no anti-endotoxin
intervention in use and (6) data was extractable into a
2 × 2 × 2 contingency table format in relation to the
co-detection of GN bacteremia and endotoxemia and
mortality proportions.
Data extraction
The patients in all studies were classified into one of
four groups as follows: both endotoxemia and GN bac-
teremia detected (group one), only GN bacteremia
detected (group two), only endotoxemia detected (group
three), and neither detected (group four). For each of
the four groups, the proportion of deaths and denomi-
nator data were extracted as a 2 × 2 × 2 contingency
table format. Additional data extracted were the type of
patient population, whether the study was undertaken in
an ICU or another setting and the bacterial species of
GN bacteremia isolates.
Data analysis
There are three objectives of this analysis. Firstly, to
determine the prognostic value associated with the
detection of GN bacteremia and endotoxemia, each
when detected in isolation (groups two and three,
respectively) and when co-detected (group one) versus
patients for whom neither was detected (group four).
This was done by deriving summary odds ratios (OR)
and 95% confidence intervals (CIs) using random effects
meta-analysis [54] together with an assessment of inter-
study statistical heterogeneity using the I2 test for group
one, group two and group three each versus group four
among the included studies [55]. This was repeated for
the sub-groups of studies that included studies of adult
patients with sepsis in an ICU setting (defined here as
high risk studies) versus studies in other settings (low
risk studies). Secondly, to visually compare individual
study results using forest and L’Abbé plots [56] the pro-
portion of deaths in groups one, two and three each ver-
sus the proportion of deaths in group four as
representing the reference group for underlying risk for
each study. The line of equality (x = y) is displayed as a
visual aid to asses dispersion of the individual study
results within each L’Abbé plot. Thirdly, to asses the
uniformity in distributions of key GN bacteremia species
type among group one and two among those studies for
which this information was available. Ethics approval
was not required for this study.
Results
Thirty-five studies [1-35] were found of which 14 stu-
dies were supplemented with data provided by personal
communication (Table 1). The survival outcome was
reported for a total of 3,235 patients among these 35
studies of which 432 (13%), 272 (8%), 1,091 (34%) and
1,440 (44%) were in groups one to four, respectively.
Patient inclusion for nine of the studies was based on
various criteria for sepsis in adult patients in an ICU
setting. A total of 26 of the 35 studies were published
within the 1980s and 1990s. The largest study [35] pro-
vided mortality data stratified in relation to endotoxemia
detection at two breakpoints.
The species types of GN bacteremia isolates were iden-
tified for 31 of the 35 studies [See Additional file 1].
Among the mono-microbial GN bacteremias, there were
174 (26%), 134 (22%), 74 (12%), and 94 (15%) bacteremias
with Escherichia coli, Enterobacteriaceae other than
E. coli (for example, Klebsiella species, Enterobacter spe-
cies), Pseudomonas aeruginosa, and Neisseria meningi-
tides, respectively. After excluding studies restricted to
specified infections, there were 497 GN bacteremias with
species type known among which there was an uneven
distribution of E. coli versus P. aeruginosa identified
among the GN bacteremias of group one versus group
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two; E. coli was less common in group one than in group
two (92 of 303 (30%) versus 82 of 194 (42%), P = 0.007;
chi-square test). By contrast, P. aeruginosa was more
common in group one than in group two (53 of 303
(17%) versus 23 of 194 (12%), P = 0.09; chi-square test).
This reciprocal mal-distribution was also apparent
among the nine studies of adults with sepsis in an ICU
setting (data not shown).
Potentially relevant studies (n = 68)
Electronic search for potentially relevant studies (n = 183)
Search terms (in title or abstract & limited to studies in humans):
¾endotoxemia
¾gram negative bacteremia
Published call for data [53] and correspondence with authors
Hand search for additional eligible studies (n = 89)
Exclusion criteria
Animal studies (n = 9)
Studies of endotoxemia without 
suspected GN bacteremia;
e.g. post exercise (n = 29)
Data insufficient (n = 54)
Studies with <10 patients (n=9)
Duplicate publication (n = 2)
Reviews and editorials (n = 91)
Eligibility criteria;
1. limulus assay used
2. ≥1 patient with GN bacteremia
3. mortality percentage derived for >5
patients in group 4
4. not receiving an anti-endotoxin antibody
5. Outcome data extractable into a 2 x 2 x 2 
contingency table format
Excluded studies;
partial catalogue in 
references [42-44]
Included studies: (Table 1; n = 35)
Studies of adult sepsis in ICU  (n = 9)
Other studies (n = 26)
Studies excluded for 
failing eligibility 
criteria;
1. n = 6
2. n = 11
3. n = 9
4. n = 2
5. n = 5
Figure 1 Flow diagram of study selection within the meta-analysis.
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Table 1 The included studies.
Study [reference] Patient population and location Numbers of patients with fatal outcome/Number tested
Group 1 Group 2 Group 3 Group 4
Gnb+ Gnb+ Gnb- Gnb-
Etx+ Etx- Etx+ Etx-
Pre-defined patient groups: Pediatric
Ahmed et al. 2004 [1] Diarrheal illness, hospitalized 3/9 1/1 1/12 1/19
Casey et al. 1992 [2] Pediatric cardiac surgery, ICU 0/1 ND 0/15 0/8
Cooperstock, 1985 [3] Suspected sepsis, hospitalized 0/10 0/1 0/6 0/26
Klein et al. 1988 [4] Malnourished children, hospitalized ND 0/1 0/7 0/8
Shenep et al. 1988 [5] Suspected sepsis, hospitalized 2/9 0/1 1/3 0/13
Pre-defined patient groups: Surgery and peri-procedural
Bailey et al. 1976 [6] Obstructive jaundice, hospitalized 1/1 ND 0/12 0/11
Berger et al. 1995 [7]a Post-colonoscopy, unspecified location 0/1 ND 0/20 0/11
Foulis et al. 1982 [8]f Acute pancreatitis, hospitalized 1/1 ND 2/12 1/13
Lau et al. 1996 [9]a Acute cholangitis, hospitalized 1/8 0/3 0/20 0/9
Lumsden et al. 1989 [10] Percutaneous biliary drainage, hospitalized 0/1 ND 0/13 0/7
Pre-defined patient groups: Specified infections
Brandtzaeg et al. 1989 [11]a Meningococcal disease, hospitalized 9/24 0/11 ND 0/7
Brandtzaeg et al. 1996 [12]a Meningococcal disease, hospitalized 21/40 0/19 1/4 3/26
Butler et al. 1973 [13]b Plague, hospitalized 1/2 ND 0/7 0/1
Butler et al. 1976 [14]b Plague, hospitalized 0/3 0/2 ND 0/5
Magliulo et al. 1976 [15]c Salmonellosis, hospitalized 0/1 ND 0/9 0/12
Magliulo et al. 1976 [15]c, d Typhoid, hospitalized 0/8 0/4 0/1 0/1
Adinolfi et al. 1987 [16]d Typhoid, hospitalized 0/7 0/7 0/2 0/5
Suyasa et al. 1995 [17]d Typhoid, hospitalized 1/4 1/6 ND 0/9
Pre-defined patient groups: Oncology and transplant patients
Bion et al. 1994 [18] Elective liver transplantation, ICU 0/1 0/1 1/31 4/19
Engervall et al. 1997 [19]a Febrile, oncology (80% neutropenic), hospitalized 1/2 0/4 0/4 0/14
Hynninen et al. 1995 [20] Febrile, oncology (43% neutropenic), hospitalized 0/3 1/24 ND 10/96
Yoshida et al. 1994 [21]a Febrile, oncology (63% neutropenic), hospitalized 14/21 1/9 11/35 8/71
Pre-defined patient groups: Other
Byl et al. 2001 [22]a Suspected sepsis, hospitalized 2/8 0/4 0/3 1/12
Giamarellos et al. 1999 [23]a Acute pyelonephritis, hospitalized 1/3 0/9 0/4 0/9
Levin et al. 1972 [24] Suspected sepsis, hospitalized 14/20 4/14 7/16 27/168
Stumacher et al. 1973 [25] Suspected bacteremia, hospitalized 6/28 15/37 2/18 4/34
Van Langervelde et al. 2000 [26]a Febrile hospital admissions, hospitalized 7/24 0/24 9/76 16/324
Adult patients in ICU with sepsis as contemporaneously defined
Bates et al. 1998 [27]a Sepsis syndrome, multi-center cohort, hospitalized 5/10 12/39 42/109 59/198
Billard et al. 1994 [28] Septic shock, ICU 5/6 ND 1/4 4/8
Danner et al. 1991 [29]a Clinically defined septic shock, ICU 4/11 0/8 8/32 12/49
Dofferhoff et al. 1992 [30] Clinically defined severe sepsis, ICU 2/4 0/2 0/6 1/6
Goldie et al. 1995 [31]a Sepsis syndrome, ICU 5/9 2/3 36/83 18/38
Guidet et al. 1994 [32]a Sepsis syndrome, ICU 13/24 4/9 14/20 18/40
Strutz et al. 1999 [33] Sepsis syndrome, ICU 1/5 3/5 5/8 4/10
Wortel et al. 1992 [34]e Sepsis syndrome, multi-center cohort, ICU 6/8 4/5 2/3 13/25
Opal et al. 1999 [35]
(Low; >20 pg/ml) a, f
Sepsis syndrome, multi-center cohort, ICU 12/51 7/21 78/255 32/128
Opal et al. 1999 [35]
(High; >660 pg/ml) a, f
Sepsis syndrome, multi-center cohort, ICU 21/63 84/241
aData for these studies [7,9,11,12,19,21-23,26,27,29,31,32,35] provided by personal communication; btwo studies of plague were aggregated for this analysis
[13,14]; cthis study stratified into two sub-studies of typhoid and salmonellosis [15]; dthree small studies of typhoid were aggregated for this analysis [15-17];
eonly the patients randomized to receive placebo from this study [34]. fthe mortality proportion data for patients with endotoxemia detected from this study [35]
has been stratified at two breakpoints, 20 and 660 pg/ml. Etx, endotoxemia; GNB, Gram negative bacteremia; ND, no data.
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Meta-analysis
The summary OR for death for group one, group two and
group three each, respectively, versus group four, are pre-
sented in Table 2 for all studies and for the subsets of ICU
and non-ICU studies. With only the nine studies underta-
ken in an ICU considered, the summary ORs were all
either not significant or borderline (OR <2).
With the 26 studies undertaken outside of an ICU set-
ting considered, the summary OR for groups one (co-
detection of endotoxemia with GN bacteremia) versus
group four was 6.9 (4.4 to 11.0) whereas the summary
OR for groups two (GN bacteremia alone) and three
(endotoxemia alone) versus group four (neither) were
not significant or borderline (OR <2).
With all 35 studies considered together, the calculated
heterogeneity was moderate (I2 = 42%) in association
with the OR derived for group one (co-detection of endo-
toxemia with GN bacteremia) versus group four from all
studies whereas the calculated heterogeneity in associa-
tion with all the other ORs was minimal (I2 = 0%).
L’Abbé and forest plots
The individual study ORs together with the summary ORs
are presented in forest plots for group one (Figure 2),
group two (Figure 3) and group three (Figure 4) all in rela-
tion to group four. The corresponding L’Abbé plots are
shown in Figure 5a, b, and Figure 5c, respectively.
The group four mortality proportion exceeded 15% for
all studies of adult patients with sepsis in an ICU setting
(high risk studies) whereas all but one of the other studies
(low risk studies) had a group four mortality proportion
<15%. The overall dispersion in the mortality proportions
away from the line of identity is most apparent in the plot
of group one versus group four (Figure 5a), in that for 17
of the 35 studies the mortality proportion in group one
was ≥20 percentage points higher in group one versus
group four. By contrast, there were only three and five stu-
dies in which the mortality proportion for group two or
group three, respectively, differed by ≥20 percentage
points versus the mortality in group four (Figure 5b and
Figure 5c).
When all the included studies here are dichotomized
into patient groups positive for endotoxemia (that is,
groups one and three aggregated) versus negative (that is,
groups two and four aggregated), there were only five stu-
dies for which a difference in mortality proportions of
≥20% was apparent in the dichotomy (data not shown)
[5,11,12,21,24]. None of these five studies were restricted
to populations of ICU patients, four had either an unu-
sually high proportion of bacteremias with P. aeruginosa
(7 of 30; [21], 7 of 34; [24]) or N. meningitidis (35 of 35;
[11], 59 of 59; [12]) among the GN bacteremias and the
fifth was a pediatric study [5] with 26 patients of which six
had bacteremias with either Hemophilus influenzae,
Campylobacter species or N. meningitidis.
Discussion
This reappraisal of this somewhat dated and disparate lit-
erature was undertaken to clarify the following as possible
confounding variables toward the prognostic value of
endotoxemia: ICU versus non-ICU setting, underlying
patient risk, and the species types and distributions of GN
bacteremia isolates within the studies. It uses L’Abbe plots
to address these questions and adds 20 studies
[1-4,6-10,12-19,22,33,35] with 9 received as personal com-
munications, not included in a previous meta-analyses
[57].
There are four findings from this analysis. The mortality
risk in each of groups one (co-detection of endotoxemia
with GN bacteremia), groups two (GN bacteremia alone)
and groups three (endotoxemia alone) versus group four
(neither) are generally either non-significant, or borderline
(OR <2) when derived from only the nine studies in an
ICU setting. However, when the 26 non-ICU studies are
considered, the risks versus group four are similar to those
derived from studies in an ICU setting with the exception
of groups one (co-detection of endotoxemia with GN bac-
teremia), which is markedly increased. Note that these
Table 2 Summary odds ratios derived from studies stratified by underlying mortality risk.
Strata of studies Groups 1 (Endotoxemia and GN
bacteremia detected) versus
groups 4 (neither detected)
Groups 2 (GN bacteremia
alone detected) versus groups
4 (neither detected)
Groups 3 (Endotoxemia alone
detected) versus groups 4
(neither detected)












ICU studies 9 1.5 0% 1.2 0% 1.4 0%
1.01 to 2.1 0.74 to 2.0 1.09 to 1.8
non-ICU studies 26 6.9 0% 1.5 0% 1.9 0%
4.4 to 11.0 0.78 to 2.7 1.2 to 2.9
All studies 35 3.1 42% 1.3 0% 1.5 0%
2.0 to 4.8 0.89 to 1.9 1.2 to 1.8
aI2 is the measure of heterogeneity in odds ratio between studies with 0% equivalent to no heterogeneity. CI, confidence interval; GN, gram negative.
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ORs for mortality risk as estimated here are all less than
those found in the previous analysis that contained fewer
studies [57].
Second, the I2 associated with each summary OR are
all 0% with the exception of that associated with the OR
for group one versus group four derived from all 35 stu-
dies. With this latter exception, this absence of hetero-
geneity is surprising given the diversity of patient
groups, underlying risk, and numbers and settings of
these studies that have been conducted and published
over a period exceeding three decades.
Third, the underlying patient risk, as reflected in the
group four mortality proportion, was higher for stu-
dies of patients with sepsis in ICU settings versus stu-
dies in other settings (Figure 5a, b, and Figure 5c), as
might be expected. However, with the notable excep-
tion of the co-detection of group one (endotoxemia
with GN bacteremia), the additional risk for each of
group two (GN bacteremia alone) and group three
(endotoxemia alone) versus group four (neither) is




Overall  (I-squared = 41.8%, p = 0.012)

































  1.1 .3 3 10 30 100
group 4 mortality higher <=> group 1 mortality higher
group1 versus group4
Figure 2 Forest plot of odds ratios for mortality for Groups 1 (Endotoxemia and GN bacteremia detected) versus groups 4 (neither
detected). Study specific and summary odds ratios (and 95% confidence intervals) derived from all 35 studies with studies sorted into those
conducted in an ICU or non-ICU setting. Arrowheads indicate 95% confidence intervals that extend out of range. GN, gram negative.
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Finally, there are important differences in the preva-
lence and species types of GN bacteremias among these
studies. Of the patients included within the studies of
this meta-analysis (not counting GN bacteremias from
studies of specified infections or studies in which the
species types of GN bacteremia was not stated), 21%
had GN bacteremia detected (group one and group two)
of which 33% were E. coli whereas only 16% were P.
aeruginosa. However, there are reciprocal differences in
the frequency of P. aeruginosa versus E. coli among the
bacteremias of groups one and two. The reciprocal dis-
tribution is a consequence of differences in endotoxemia
detection rates, being more common for GN bactere-
mias with P. aeruginosa versus E. coli. This reciprocal
distribution for different GN bacteremia species types is
apparent among a broader collection of studies that
used the limulus assay [43]. Likewise, among 57 GN
bacteremias found in a therapeutic trial in patients with
septic shock selected on the basis of a positive detection
of endotoxemia using the limulus assay, 15 versus only
12 of the GN bacteremias were P. aeruginosa versus E.
coli, respectively [58].
The relative frequencies of bacteremias with P. aerugi-
nosa versus bacteremias with E. coli among the studies
.
.



















Subtotal  (I-squared = 0.0%, p = 0.828)
Magliulo & Adinolfi (Typhoid) [15&16]
Engervall [19]






  1.03 .1 .3 3 10 30 100
group 4 mortality higher <=> group 2 mortality higher
group2 versus group4
Figure 3 Forest plot of odds ratios for mortality for Groups 2 (GN bacteremia alone) versus groups 4 (neither detected). Study specific
and summary odds ratios (and 95% confidence intervals) derived from all 35 studies with studies sorted into those conducted in an ICU or non-
ICU setting. Arrowheads indicate 95% confidence intervals that extend out of range. GN, gram negative.
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are of interest for two reasons. The mortality risk for
these two common bacteremias differs [59]. For exam-
ple, in the literature experience over thirty years to
2004, the mortality associated with P. aeruginosa bacter-
emia was typically 32% versus the mortality associated
with E. coli bacteremia which was typically 19% [60].
The basis for this higher mortality risk is multi-factorial
with patient [47,61] and treatment [62,63] factors contri-
buting. Also of interest are the structural differences in
lipid-A, the biologically active component of endotoxin
(lipopolysaccharide, LPS) [45], specific for P. aeruginosa
versus E. coli. The different lipid-A structures of P.
aeruginosa versus E. coli confer potency differences
which are apparent in vitro [64,65], and in vivo [66].
While the clinical significance of these potency differ-
ences is unclear, the resulting unequal distributions of
bacteremias among groups one and two uncovered here
may confound the apparent relationship between endo-
toxemia and mortality risk.
Limitations
This overview is based on a summation of disparate
observational studies in an attempt to identify confoun-
ders underlying the disparate observations regarding
.
.























Subtotal  (I-squared = 0.0%, p = 0.717)
Magliulo & Adinolfi (Typhoid) [15&16]
Billard [28]












  1.03 .1 .3 3 10 30
group 4 mortality higher <=> group 3 mortality higher
group3 versus group4
Figure 4 Forest plot of odds ratios for mortality for Groups 3 (Endotoxemia alone) versus groups 4 (neither detected). Study specific
and summary odds ratios (and 95% confidence intervals) derived from all 35 studies with studies sorted into those conducted in an ICU or non-
ICU setting. Arrowheads indicate 95% confidence intervals that extend out of range.
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endotoxemia and mortality risk in the literature. This
analysis is unable to identify the mechanism for any
increased risk. Many relevant patient specific details
such as age and co-morbidities for the patients of the
four groups in each study were not available. In this
analysis, a variable proportion of blood cultures that
were classified as negative for GN bacteria would have
yielded gram positive bacteremias or fungemias. The
Figure 5 L’Abbé plots of study specific mortality rates. Each figure shows mortality rates for studies undertaken in an ICU (triangles) or non-
ICU (circles) setting with symbols proportional to group size with the line of no difference (y = x; dotted line) shown for visual reference
purposes. Shown are Groups 1 (endotoxemia and GN bacteremia detected) versus groups 4 (neither detected) (Figure 5a - top), Groups 2 (GN
bacteremia alone) versus groups 4 (neither detected) (Figure 5b - middle), and Groups 3 (endotoxemia alone) versus groups 4 (neither detected)
(Figure 5c - bottom). GN, gram negative.
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detection of endotoxemia in association with blood cul-
ture isolates other than GN bacteremias is a commonly
reported finding [25,41]. In this respect, the prognostic
impact of blood stream infections other than GN bacter-
emias in relation to the co-detection with endotoxemia
has not been addressed here. Moreover, the origin of
endotoxemia for patients in group three is uncertain
and the possibility of endotoxin originating from other
sources, such as gut barrier breakdown, as is presumed
to occur for non-septic forms of shock, needs to be con-
sidered [67]. Also, it needs to be noted that endotoxe-
mia and GN bacteremia are each either episodic or
dynamic [68] phenomena and the criteria for a positive
detection of each will have differed among the studies.
The additional mortality associated the co-detection of
endotoxemia and GN bacteremia (group one) was less
apparent in the studies of patients at high versus low
underlying risk (Table 1). This finding here at a group
level of analysis resembles other recent findings at an
individual patient level of analysis among bacteremias of
all species types occurring in an ICU setting [46]. How-
ever, this inference requires caution for three reasons.
Firstly, it needs to be clarified as to whether the
increased risk is absolute [47] or relative [46].
Second, the proportion of GN bacteremia types that
are other than E. coli is more variable in studies outside
of the ICU setting. In particular, there were five non-
ICU studies [5,11,12,21,24] with an unusually high pro-
portion of isolates other than E. coli among the GN
bacteremias.
Third, it should be cautioned that the L’Abbé plots are
useful merely as simple graphical methods to facilitate
visual comparisons of the group mortality proportion
over the range of underlying risk as found in individual
studies within a meta-analysis [56]. The issues underlying
the statistical testing for variation in either additional risk
or treatment effect in relation to underlying risk are not
simple [69,70]. In particular, where linear regression has
been used within L’Abbe plots to explore heterogeneity
over a range of underlying risk in other contexts, regres-
sion to the mean is an important consideration as noted
among treatment studies of mild hypertension [71].
In this analysis, group four, which is usually the largest
group in each study, serves not only as the reference
group for each study in the derivation of the ORs (Table
2) but also as a surrogate marker for the underlying mor-
tality risk within each study (Figures 5a, b, and Figure
5c). However, this proportion will be an imprecise mar-
ker in small studies and studies with less restrictive
patient selection. As a consequence of this imprecision,
proportion estimates from small studies will have refer-
ence and comparator groups that by chance will be either
more or less extreme than the average and hence, the
accompanying comparator or reference group,
respectively, will tend to be closer to the mean [72]. This
regression to the mean will cause these outlier studies to
have a disproportionate impact on the overall relation-
ship with underlying risk and will tend to inflate any
deviation of a derived regression relationship with under-
lying risk away from the null. In the analysis here how-
ever, linear regression has not been used and the studies
that trended away from the null in the L’Abbe plots were
generally neither the smaller studies nor the studies with
high event rates among group four.
There were insufficient studies that had used assays
other than the limulus assay, or patient groups that had
received anti-endotoxin antibodies to include these stu-
dies so as to enable a study of these variables by meta-
regression. Only seven studies [11-17] were limited to
specific GN bacteremia species types. Also, many rele-
vant study level details, such as method of blood culture
used and antibiotic therapy protocols were not available.
Anti-endotoxin antibodies are detectable in patients
with severe sepsis and septic shock and the kinetics of
these antibodies over time differs between survivors and
non-survivors [73]. However, the impact of these anti-
endotoxin antibodies on both the detection of endotoxe-
mia and possibly also on patient outcome within the
studies examined here is uncertain. A more detailed
examination adjusting for relevant prognostic variables
contributing to underlying patient level risk and also the
inter-relation between various GN bacteria known to
have differing lipid-A structures would require an indivi-
dual patient data meta-analysis.
With these findings, it is now possible to re-appraise
the relationship between endotoxemia detection and
mortality risk as observed in the broader literature.
With the patient populations dichotomized into endo-
toxemia positive versus negative, only five
[5,11,12,21,24] of the 35 studies included in this analysis
found differences in mortality proportions exceeding 20
percentage points (data not shown) and in all five of
these studies there was an unusually high proportion of
isolates other than E. coli (for example, P. aeruginosa or
N. meningitidis) among the GN bacteremias and none
of these five studies were restricted to ICU populations.
There were a further four large studies in an ICU set-
ting [36-39] that had not been included in this analysis
as the mortality proportions were not extractable into a
2 × 2 × 2 contingency table format or used endotoxemia
assays other than the limulus assay. None of these four
additional studies found differences in mortality propor-
tions exceeding 15 percentage points between endotoxe-
mia positive versus negative patients. While one study
had E. coli accounting for two of the four GN bactere-
mias [38], the GN bacteremia species types were not
stated in the other three studies. One large non-ICU
study did not report mortality as an outcome [40].
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While some of the studies were conducted more than
thirty years ago, they remain of interest due to the unre-
solved conflicting conclusions that continue to emerge.
These large studies are difficult and expensive to under-
take. An understanding of the previous uncertainties
would assist in the planning of any further studies to be
undertaken.
The extent to which the species type and prevalence
of GN bacteremia confounds the relationship between
the detection of endotoxemia and outcome and in the
evaluation of anti-endotoxin and other adjuvant thera-
pies for sepsis warrants further consideration [74-76].
Conclusions
The underlying patient risk and the GN bacteremia spe-
cies types within a study may be unrecognized confoun-
ders in the interpretation of the predictive value of
endotoxemia. This may not only help to resolve conflicting
observations in the clinical literature but may also help to
bridge the ‘disconnect’ with animal models of sepsis. Clari-
fication will help toward defining the exact role of endo-
toxemia within the pathogenesis of GN sepsis and the
evaluation of anti-endotoxin and other adjuvant therapies
for sepsis.
Key messages
• There are conflicting conclusions regarding the
prognostic value of endotoxemia detection among
more than forty studies in various ICU and non-ICU
settings.
• Using the limulus assay for endotoxemia detection,
less than two thirds of patients with GN bacteremia
have endotoxemia detected and vice versa.
• The mortality risk in association with the detection
of endotoxemia or GN bacteremia either alone or
together versus the detection of neither is generally
either non-significant or borderline (OR <2) when
derived from only the nine studies in an ICU setting.
• The co-detection of GN bacteremia and endotoxe-
mia is most predictive of increased mortality risk
versus the detection of neither but only in studies
undertaken outside of an ICU setting.
• Variation in GN bacteremia species types and
underlying risk are likely unrecognized confounders
in the individual studies.
Additional material
Additional file 1: GN bacteremia types and distributions.
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